Literature DB >> 33104078

Infliximab in acute severe colitis: getting the right dose.

Joseph Fiske1, Thomas Conley1, Shaji Sebastian2, Sreedhar Subramanian1.   

Abstract

Acute severe colitis is a medical emergency and requires prompt treatment with intravenous steroids. Infliximab is typically used as rescue therapy in those who fail to respond to corticosteroids. This article outlines the altered pharmacokinetics of infliximab in acute severe UC and summarised the latest published data surrounding accelerated infliximab dosing. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  clinical decision making; inflammatory bowel disease; infliximab; ulcerative colitis

Year:  2020        PMID： 33104078      PMCID： PMC7569519          DOI： 10.1136/flgastro-2020-101407

Source DB:  PubMed          Journal:  Frontline Gastroenterol        ISSN： 2041-4137


  13 in total

1.  An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis.

Authors:  David J Gibson; Zaid S Heetun; Ciaran E Redmond; Kavin S Nanda; Denise Keegan; Kathryn Byrne; Hugh E Mulcahy; Garret Cullen; Glen A Doherty
Journal:  Clin Gastroenterol Hepatol       Date:  2014-07-30       Impact factor: 11.382

Review 2.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Authors:  Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne
Journal:  Gut       Date:  2019-09-27       Impact factor: 23.059

3.  Infliximab induction regimens in steroid-refractory acute severe colitis: a multicentre retrospective cohort study with propensity score analysis.

Authors:  Shaji Sebastian; Sally Myers; Konstantinos Argyriou; Gayle Martin; Louis Los; Joseph Fiske; Ravi Ranjan; Benjamin Cooper; Vivek Goodoory; Hey-Long Ching; NishaniLalanthika Jayasooriya; Johanne Brooks; Anjan Dhar; Achut H Shenoy; Jimmy K Limdi; Jeffrey Butterworth; Patrick B Allen; Sunil Samuel; Gordon W Moran; Richard Shenderey; Gareth Parkes; Alan Lobo; Nicholas A Kennedy; Sreedar Subramanian; Tim Raine
Journal:  Aliment Pharmacol Ther       Date:  2019-09       Impact factor: 8.171

Review 4.  Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms.

Authors:  Ingrid Ordás; Diane R Mould; Brian G Feagan; William J Sandborn
Journal:  Clin Pharmacol Ther       Date:  2012-02-22       Impact factor: 6.875

5.  Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative Colitis.

Authors:  Matthew C Choy; Dean Seah; David M Faleck; Shailja C Shah; Che-Yung Chao; Yoon-Kyo An; Graham Radford-Smith; Talat Bessissow; Marla C Dubinsky; Alexander C Ford; Leonid Churilov; Neville D Yeomans; Peter P De Cruz
Journal:  Inflamm Bowel Dis       Date:  2019-06-18       Impact factor: 5.325

6.  Significance of systemic endotoxaemia in inflammatory bowel disease.

Authors:  K R Gardiner; M I Halliday; G R Barclay; L Milne; D Brown; S Stephens; R J Maxwell; B J Rowlands
Journal:  Gut       Date:  1995-06       Impact factor: 23.059

7.  Pharmacokinetics of infliximab in children with moderate-to-severe ulcerative colitis: results from a randomized, multicenter, open-label, phase 3 study.

Authors:  Omoniyi J Adedokun; Zhenhua Xu; Lakshmi Padgett; Marion Blank; Jewel Johanns; Anne Griffiths; Joyce Ford; Honghui Zhou; Cynthia Guzzo; Hugh M Davis; Jeffrey Hyams
Journal:  Inflamm Bowel Dis       Date:  2013-12       Impact factor: 5.325

8.  Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis.

Authors:  B Ungar; Y Mazor; R Weisshof; H Yanai; Y Ron; I Goren; A Waizbard; M Yavzori; E Fudim; O Picard; R Loebstein; U Kopylov; I Dotan; Y Chowers; R Eliakim; S Ben-Horin
Journal:  Aliment Pharmacol Ther       Date:  2016-04-19       Impact factor: 8.171

9.  Practice pattern variability in the management of acute severe colitis: a UK provider survey.

Authors:  Shaji Sebastian; Jessica Lisle; Sreedhar Subramanian; Anjan Dhar; Achut Shenoy; Jimmy Limdi; Jeffrey Butterworth; Patrick B Allen; Sunil Samuel; Gordon Moran; Richard Shenderey; Gareth Parkes; Tim Raine; Alan J Lobo; Nicholas A Kennedy
Journal:  Frontline Gastroenterol       Date:  2019-08-17

10.  Thirty-day mortality after elective and emergency total colectomy in Danish patients with inflammatory bowel disease: a population-based nationwide cohort study.

Authors:  Anders Tøttrup; Rune Erichsen; Claus Sværke; Søren Laurberg; Henrik Toft Srensen
Journal:  BMJ Open       Date:  2012-04-05       Impact factor: 2.692
View more
  1 in total

1.  Efficacy of Infliximab Dose Escalation in Patients with Refractory Immunotherapy-Related Colitis: A Case Series.

Authors:  Jessica P Harris; Michael A Postow; David M Faleck
Journal:  Oncologist       Date:  2022-04-05       Impact factor: 5.837
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.